Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E 21 versus GENCEPT 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E 21 versus GENCEPT 10 11 28.
ENOVID-E 21 vs GENCEPT 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive